Skip to content

    Strides Pharma Science Limited

    STAR
    Healthcare·27 May 2025
    Management Summary

    Strides Pharma delivered a strong Q4 and FY25, exceeding guidance on revenue, EBITDA, and US sales. The company demonstrated significant operating leverage, leading to a 12x growth in operational PAT and an improved Net Debt to EBITDA ratio of 1.9x. A dividend of INR 4 per share was approved, reflecting robust financial performance and a focus on shareholder returns, despite some uncertainties regarding US tariffs and slight degrowth in access markets.

    Highlights

    7

    • FY25 Revenue grew 17.2%, surpassing the 12-15% guidance.

    • FY25 EBITDA of INR 802.8 crores exceeded the INR 750-800 crores guidance range, growing 37% YoY.

    • Q4 FY25 EBITDA grew 22% YoY to INR 218 crores, with an EBITDA margin of 18.3%.

    • FY25 Net Debt to EBITDA improved to 1.9x, better than the 2x target.

    • Operational PAT for FY25 grew almost 12x, and Q4 operational PAT was INR 113 crores, a new high.

    • US revenue reached $291 million, exceeding the $275-290 million guidance, and grew 22% YoY.

    • ROCE improved to 14.9% from 9.7% (comparable basis).

    Concerns

    2

    • Access markets experienced a slight degrowth in FY25, though management expects new initiatives to drive future growth.

    • Potential impact of US tariffs remains an uncertainty, though management believes they can pass on costs.

    What Changed3

    vs Q1 FY26

    Guidance items11 → 9 (-2)Risks discussed4 → 1 (-3)Q&A highlights8 → 6 (-2)
    Key financials

    Metrics

    9

    Periods

    2

    Q4 FY25

    2
    • EBITDA
      ₹218 Cr
      YoY+22%
    • EBITDA Margin
      18.3%

    FY25

    7
    • Revenue Growth
      17.2%
    • EBITDA
      ₹802.8 Cr
      YoY+37%
    • EBITDA Margin
      17.6%
    • Operational EPS
      ₹37.46
      YoY+11%
    • Reported EPS
      ₹44.05

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Gross ₹1,800 crores · Net ₹1,522 crores · 1.9x EBITDA

    Cost 9.0%

    Dividend

    ₹4/share (interim)

    Guidance & targets

    9
    CategoryTargetPriority
    Revenue
    US Business Revenue
    $400 million
    		High
    R&D Spend
    Total R&D Spend
    almost doubling
    		Medium
    R&D Spend
    R&D Spend for Beyond $400M Play
    $15 million of $20 million
    		High
    Capex
    Capex Outlook
    similar or lower levels
    		Medium
    EBITDA Margin
    EBITDA Margin
    close to 20%
    		Medium
    Debt
    Debt Reduction
    INR 1,000 crores
    		Medium
    Product Launches
    Nasal Spray Products Commercialization
    between 12 and 18 months
    		High
    Product Filings
    505(b)(2) Filings
    3 to 4 products
    		High
    Product Approvals
    505(b)(2) Approvals
    4 approvals
    		Medium

    US Business Revenue Target

    next 2 years
    Current$291 million (FY25)
    TargetProgress towards $400 million

    Why it matters

    Achievement of this target is crucial for the company's overall growth strategy and US market expansion.

    Our $400 million objective has been up in our slides now for a good 3 years.

    How to verify

    key_financials.metrics[label='FY25 US Revenue']

    Risks & concerns

    1
    RiskSeverity

    US Tariffs

    Potential US tariffs on generics, though management plans to pass on costs, which may cause a lag in new pricing. — Both acknowledged

    medium

    Q&A highlights

    6

    “The U.S. plant that we acquired from Endo has a very significant controlled substance opportunity across all domains. Our first we have 3 filings in our nasal spray programs, which will all be completed within the year. The market opportunity of this is very significant.”

    Clarifies the strategic importance of the Endo acquisition and the potential of the nasal spray pipeline for the US market.

    asked by Aniket Nikumb

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Financial Performance Exceeding Guidance

    Strides Pharma delivered a robust financial performance for FY25, with revenue growing 17.2%, surpassing the guided range of 12-15%. EBITDA for the year reached INR 802.8 crores, exceeding the higher end of the INR 750-800 crores guidance, and marked a 37% YoY growth with an EBITDA margin of 17.6%. The company also reported its highest ever operational PAT, growing almost 12x from the previous year, and an operational EPS of INR 37.46 per share.

    02

    US Business Outperformance and Strategic Focus

    The US business was a key driver, achieving $291 million in revenue, which exceeded the $275-290 million guidance and represented a 22% growth. Management reiterated its $400 million objective for the US market. The company's strategy in the US involves focusing on product selection, service levels, and leveraging its acquired US plant for controlled substance opportunities, with 3 nasal spray filings expected to commercialize within 12-18 months.

    03

    Improved Capital Structure and Shareholder Returns

    Strides significantly deleveraged its balance sheet, reducing net debt by INR 513 crores during FY25 to INR 1,522 crores, resulting in a Net Debt to EBITDA ratio of 1.9x, better than the 2x outlook. Gross debt was reduced by INR 619 crores. The Board approved a dividend of INR 4 per share, reflecting confidence in the company's financial health and commitment to shareholder returns. The current cost of funds is approximately 9%.

    04

    R&D Investment in Complex Products

    The company plans to significantly increase its R&D spend, almost doubling it from last year, with approximately $15 million out of $20 million allocated to the 'Beyond $400 million' strategy, primarily focusing on 505(b)(2) products. Strides expects to file 3-4 such products annually and anticipates around 4 approvals per year, with the first nasal spray product already filed with the US FDA.

    05

    Operational Efficiency and Margin Expansion

    Operational efficiency was a key theme, with gross margins maintained in the 58-59% range for the last two quarters post-demerger. The EBITDA to PAT conversion for Q4 FY25 was 52%, a significant improvement. The cash-to-cash cycle improved to 117 days, contributing to INR 684 crores in operational cash flow and INR 230 crores in free cash after INR 242 crores in capex. The company aims to reach an EBITDA margin close to 20% within the next three years.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.